pelacarsen Cardiovascular, Renal and Metabolic Phase 3 2025 ASO targeting Lp(a) Secondary prevention of cardiovascular events in patients with elevated levels of Lipoprotein(a) (CVRR-Lp(a)) Lead Indication PrintPDF